Abstract
Introduction: Glargine U300 (GLA-300) has a better pK/pD profile compared to Glargine U100 (GLA-100) resulting in a flatter action profile that fulfills the criterion of an ideal basal insulin . This retrospective real world study from Eastern India looks at the efficacy and safety of GLA-300 compared to GLA-100 used in insulin naive diabetic subjects presenting with oral anti diabetic (OAD) failure.
Materials and Methods: Anthropometric data, blood pressure, glycaemic parameters, creatinine, and insulin dosage at baseline and after a treatment period of 12 weeks were taken up for analysis retrospectively.
Results: Fasting, postprandial and HbA1C values were reduced significantly for both 54 patients in GLA-300 arm and 50 patients in GLA-100 arm. No change observed in anthropometric parameters, blood pressure and creatinine values between the two arms. Incremental dose of +5.41±0.69 units for GLA-300 cohort was required in contrast to 10.66±1.04 units for GLA 100 cohort. There were 6 episodes of hypoglycaemia in the GLA-300 cohort and 11 in the GLA-100 cohort.
Conclusion: GLA-300 appears to be a safer compared to GLA 100 as effective basal insulin.
Conflict of Interest
The authors declare no conflict of interest.
Ethical Approval
Not applicable
Data Availability
The datasets used in this study are openly available at [repository link] and the source code is available on GitHub at [GitHub link].
Cite this article
Related Research
